Prognostic value of serum p53 antibodies in patients with resected non-small cell lung cancer

被引:27
作者
Laudanski, J
Burzykowski, T
Niklinska, W
Chyczewski, L
Furman, M
Niklinski, J
机构
[1] Bialystok Med Univ, Dept Thorac Surg, PL-15276 Bialystok, Poland
[2] Limburgs Univ Ctr, Ctr Stat, B-3590 Diepenbeek, Belgium
[3] Bialystok Med Univ, Dept Histol, PL-15276 Bialystok, Poland
[4] Bialystok Med Univ, Dept Pathol, PL-15276 Bialystok, Poland
关键词
serum p53 antibodies; lung cancer; prognosis;
D O I
10.1016/S0169-5002(98)00088-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Serum antibodies against p53 protein (p53-Abs) have been detected in some cancer patients. The significance and use of p53-Abs as a marker of the clinical behavior of lung cancer is currently under investigation. Purpose: In this study, we measured the serum p53-Abs in 84 patients with operable non-small cell lung cancer (NSCLC)and evaluated potential association between the presence of these antibodies and prognosis. Methods: Enzyme-linked immunosorbent assay (ELISA) was used to detect p53-Abs in serum. Survival and disease-free survival curves related to initial p53-Abs status were estimated using the Kaplan-Meier method. Results: At the time of diagnosis 19 (22.6%) of 84 analyzed patients had positive result from the serum p53 antibodies (p53-Abs) test. No association was found between p53-Abs, histological types of tumors and clinical stage of disease. We found that patients with a positive result from the p53-Abs test had lower probability of overall and disease-free survival. The unfavorable effect was significant both in the univariate analysis, as well as in the multivariate analysis (after adjustment for sex, histopathological type of tumor, TNM stage). Conclusion: The results of the present study indicate that serum p53 antibodies may be an independent prognostic factor in NSCLC, especially in the squamous cell carcinoma (SqCC) patients and may be useful in identifying resected lung cancer patients at high risk for treatment failure. (C) 1998 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:191 / 200
页数:10
相关论文
共 24 条
[1]  
Agresti A., 1990, Analysis of categorical data
[2]   PREVALENCE OF SERUM ANTIBODIES AGAINST THE P53 TUMOR-SUPPRESSOR GENE PROTEIN IN VARIOUS CANCERS [J].
ANGELOPOULOU, K ;
DIAMANDIS, EP ;
SUTHERLAND, DJA ;
KELLEN, JA ;
BUNTING, PS .
INTERNATIONAL JOURNAL OF CANCER, 1994, 58 (04) :480-487
[3]   Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma [J].
Bourhis, J ;
Lubin, R ;
Roche, B ;
Koscielny, S ;
Bosq, J ;
Dubois, I ;
Talbot, M ;
Marandas, P ;
Schwaab, G ;
Wibault, P ;
Luboinski, B ;
Eschwege, F ;
Soussi, T .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (17) :1228-1233
[4]   DETECTION OF ANTIBODIES AGAINST THE CELLULAR PROTEIN P53 IN SERA FROM PATIENTS WITH BREAST-CANCER [J].
CRAWFORD, LV ;
PIM, DC ;
BULBROOK, RD .
INTERNATIONAL JOURNAL OF CANCER, 1982, 30 (04) :403-408
[5]   GENDER COMPARISONS IN HUMAN LUNG-CANCER - ANALYSIS OF P53 MUTATIONS, ANTI-P53 SERUM ANTIBODIES AND C-ERBB-2 EXPRESSION [J].
GUINEE, DG ;
TRAVIS, WD ;
TRIVERS, GE ;
DEBENEDETTI, VMG ;
CAWLEY, H ;
WELSH, JA ;
BENNETT, WP ;
JETT, J ;
COLBY, TV ;
TAZELAAR, H ;
ABBONDANZO, SL ;
PAIROLERO, P ;
TRASTEK, V ;
CAPORASO, NE ;
LIOTTA, LA ;
HARRIS, CC .
CARCINOGENESIS, 1995, 16 (05) :993-1002
[6]   CLINICAL IMPLICATIONS OF THE P53 TUMOR-SUPPRESSOR GENE [J].
HARRIS, CC ;
HOLLSTEIN, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (18) :1318-1327
[7]  
JOHNSON BE, 1993, CHEST, V103, pS1
[8]  
Kalbfleisch JD., 2011, The statistical analysis of failure time data
[9]  
Komiya T, 1997, ANTICANCER RES, V17, P3721
[10]  
LABRECQUE S, 1993, CANCER RES, V53, P3468